Physician profile
Hashem Azad
NPI 1780945980
$5,228.21
in general payments reported to CMS, 2019-2025
31 companies · $1,108 in 2025
The $1,108 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $458 · 2021: $1,168 · 2022: $607 · 2023: $842 · 2024: $433 · 2025: $1,108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,383.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,416.59 | 2019-2023 | Xarelto |
| Amgen INC. | $466.15 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $353.48 | 2019-2025 | |
| Pfizer INC. | $249.08 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.23 | 2023-2025 | Jardiance |
| Cvrx, INC. | $227.37 | 2020-2025 | Barostim Neo System |
| Apyx Medical Corporation | $218.15 | 2020 | |
| Alnylam Pharmaceuticals INC. | $213.65 | 2019-2025 | Onpattro |
| Edwards Lifesciences Corporation | $173.09 | 2025 | |
| Abbott Laboratories | $166.74 | 2021 | |
| Novo Nordisk INC | $166.22 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Akcea Therapeutics, INC. | $121.76 | 2019 | |
| Kestra Medical Technology Services, INC. | $118.20 | 2023 | Assure Wcd |
| Esperion Therapeutics, INC. | $111.33 | 2021 | |
| Boston Scientific Corporation | $111.12 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $105.02 | 2020 | |
| Cardiva Medical, INC. | $99.91 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $91.29 | 2022-2025 | Farxiga |
| Astellas Pharma US INC | $87.34 | 2019 | |
| Merck Sharp & Dohme LLC | $75.14 | 2021-2023 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $50.58 | 2022-2024 | Lifevest |
| Bridgebio Pharma, INC. | $48.11 | 2025 | Attruby |
| Bayer Healthcare Pharmaceuticals INC. | $46.83 | 2023 | |
| Scpharmaceuticals INC. | $45.87 | 2024-2025 | |
| Lexicon Pharmaceuticals, INC. | $45.31 | 2023 | Inpefa |
| Lilly USA, LLC | $40.48 | 2025 | Zepbound, Mounjaro |
| Cleerly, INC. | $34.24 | 2025 | Cleerly Labs, Cleerly Ischemia |
| E.R. Squibb & Sons, L.L.C. | $34.15 | 2022-2025 | Eliquis |
| Impulse Dynamics (USA) INC. | $30.02 | 2023 | Optimizer |
| Vital Connect, INC | $23.31 | 2023 | Vitalpatch Rtm |
| Infobionic, INC | $18.45 | 2023 | Mome Kardia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hashem Azad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.